Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides - PubMed (original) (raw)

Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides

Emmet B Keeffe et al. World J Gastroenterol. 2009.

Abstract

Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum. More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis C virus was recognized in in vitro systems. These basic studies led to phase II clinical trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon, with or without ribavirin, in the treatment of chronic hepatitis C genotype 4. The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin. In very preliminary studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approximately a quarter of patients. Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway, new second generation and controlled release thiazolides are being developed, and future studies of patients with chronic hepatitis B are planned.

PubMed Disclaimer

Similar articles

• Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C.
  Rossignol JF, Keeffe EB. Rossignol JF, et al. Future Microbiol. 2008 Oct;3(5):539-45. doi: 10.2217/17460913.3.5.539. Future Microbiol. 2008. PMID: 18811238 Review.
• Thiazolides: a new class of antiviral drugs.
  Rossignol JF. Rossignol JF. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. doi: 10.1517/17425250902988487. Expert Opin Drug Metab Toxicol. 2009. PMID: 19442032 Review.
• Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.
  Kohla MA, El-Said H, El-Fert A, Ehsan N, Ezzat S, Taha H. Kohla MA, et al. Eur J Gastroenterol Hepatol. 2016 Jan;28(1):42-7. doi: 10.1097/MEG.0000000000000492. Eur J Gastroenterol Hepatol. 2016. PMID: 26473300 Clinical Trial.
• Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
  Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Rossignol JF, et al. Gastroenterology. 2009 Mar;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 Nov 19. Gastroenterology. 2009. PMID: 19135998 Clinical Trial.
• Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
  Rossignol JF, Elfert A, Keeffe EB. Rossignol JF, et al. J Clin Gastroenterol. 2010 Aug;44(7):504-9. doi: 10.1097/MCG.0b013e3181bf9b15. J Clin Gastroenterol. 2010. PMID: 20048684

Cited by

• Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency.
  Perelygina L, Hautala T, Seppänen M, Adebayo A, Sullivan KE, Icenogle J. Perelygina L, et al. Antiviral Res. 2017 Nov;147:58-66. doi: 10.1016/j.antiviral.2017.09.019. Epub 2017 Sep 30. Antiviral Res. 2017. PMID: 28974385 Free PMC article.
• Broad-spectrum antivirals against viral fusion.
  Vigant F, Santos NC, Lee B. Vigant F, et al. Nat Rev Microbiol. 2015 Jul;13(7):426-37. doi: 10.1038/nrmicro3475. Epub 2015 Jun 15. Nat Rev Microbiol. 2015. PMID: 26075364 Free PMC article. Review.
• Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells.
  Zhou H, Su X, Lin L, Zhang J, Qi Q, Guo F, Xu F, Yang B. Zhou H, et al. Viruses. 2019 Aug 13;11(8):742. doi: 10.3390/v11080742. Viruses. 2019. PMID: 31412574 Free PMC article.
• Experimental Pharmacotherapy for COVID-19: The Latest Advances.
  Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Pagliano P, et al. J Exp Pharmacol. 2021 Jan 7;13:1-13. doi: 10.2147/JEP.S255209. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33442304 Free PMC article. Review.
• New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agents.
  Saleh M, Mostafa YA, Kumari J, Thabet MM, Sriram D, Kandeel M, Abdu-Allah HHM. Saleh M, et al. RSC Med Chem. 2023 Oct 10;14(12):2714-2730. doi: 10.1039/d3md00449j. eCollection 2023 Dec 13. RSC Med Chem. 2023. PMID: 38107181 Free PMC article.

References

1. 1. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67:1947–1967. - PubMed
2. 1. Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, Elfert A, Puglisi J, Rossignol JF, Glenn JS. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract] Hepatology. 2008;48:1151A.
3. 1. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56–63. - PubMed
4. 1. Schaninger T, Hong J, Luo GG. Nitazoxanide inhibits hepatitis C virus replication in vitro [abstract] Hepatology. 2008;48:756A.
5. 1. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069–4071. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Baishideng Publishing Group Inc.
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database